Centocor Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Philadelphia PA United States (1979)
Status: Acquired by Johnson and Johnson (1999)

Organization Overview

First Clinical Trial
1991
NCT00269893
First Marketed Drug
1994
abciximab (Reopro)
First NDA Approval
1996
imciromab pentetate (myoscint)
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Centocor BV | Centocor, Inc. | CENTOCOR INC | Centocor Ortho Biotech, Inc. | Centocor Ortho Biotech Services, L.L.C. | Centocor Research & Development, Inc.